Elevation Oncology, Inc.
elevationoncology.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 15, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 15, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody-drug conjugate cancer therapies for patients with solid tumors, including gastric, breast and lung cancers.
10-K for FY2024, filed Mar 6, 2025We are an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a…View ↗
Our lead product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2…View ↗
Our second product candidate, EO-1022, is a potentially differentiated HER3 ADC being developed for the treatment of patients with…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 6, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 15, 2025
−$14.2MView ↗
- ▲ +33% (Loss)
- vs −$10.7M in Q1 FY2024
-
Jul 23, 2025
Concentra acquired Elevation Oncology
The merger made Elevation a wholly owned subsidiary; shareholders received cash and contingent value rights.
Sources
8-K, filed Jul 23, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on July 23, 2025, Merger Sub completed a tender…View ↗
-
Jul 2, 2025
Elevation ended its license with CSPC
The licensed rights reverted to CSPC, and no further payments were due under the license.
Sources
8-K, filed Jul 2, 2025
On June 26, 2025 (the “Effective Date”), Elevation Oncology, Inc. (the “Company”) entered into a Mutual Release and Termination Agreement…View ↗
-
Mar 20, 2025
Elevation stopped EO-3021 development and continued EO-1022
The company also began reviewing strategic options.
Sources
8-K, filed Mar 20, 2025
On March 20, 2025, Elevation Oncology, Inc. (the “Company”) announced that it has elected to discontinue development of EO-3021, a Claudin…View ↗
Who Did They Compete With?
Competes with Antengene, AstraZeneca, Chia Tai Tianqing Pharmaceutical, Evopoint Biosciences, Innovent Biologics, LaNova Medicines, Merck KGaA, Jiangsu Hengrui, RemeGen, Shanghai Junshi Bioscience, Sichuan Kelun-Biotech Biopharmaceutical, SystImmune, TORL Biotherapeutics, Astellas Pharma, Alphamab Oncology, Daiichi Sankyo/Merck, Duality Biologics, MediLink Therapeutics (Suzhou)/BioNTech, Multitude Therapeutics, and Merus
10-K for FY2024, filed Mar 6, 2025There are a number of biological and biotechnology companies that currently are pursuing the development of selective cancer therapies for…View ↗
Loading...
